enVVeno Medical Corp (NVNO) stock
NVNONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$5.77+0.00 (0.00%)
Close on Nov 18, 2026Market cap $4.01MP/E –Yield –
enVVeno Medical r&d expenses
Research and development expenses are spending on new products and technology.
enVVeno Medical's R&D Expenses for the twelve months ending Sep 30, 2026 was $9.01M, down 22.0% year over year. For fiscal 2025 it was $9.98M, down 18.5% from the year before. The highest annual figure on record is $13.58M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.98M | -18.5% |
| FY2024 | Dec 31, 2024 | $12.25M | -9.8% |
| FY2023 | Dec 31, 2023 | $13.58M | +37.0% |
| FY2022 | Dec 31, 2022 | $9.91M | +73.1% |
| FY2021 | Dec 31, 2021 | $5.73M | +34.7% |
| FY2020 | Dec 31, 2020 | $4.25M | +92.7% |
| FY2019 | Dec 31, 2019 | $2.21M | +78.1% |
| FY2018 | Dec 31, 2018 | $1.24M | +90.7% |
| FY2017 | Dec 31, 2017 | $649.74K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.88M | +11.3% |
| Q2 FY2026 | Jun 30, 2026 | $2.08M | -28.2% |
| Q1 FY2026 | Mar 31, 2026 | $2.11M | -17.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.95M | -44.5% |
| Q3 FY2025 | Sep 30, 2025 | $2.59M | -9.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.89M | +2.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.56M | -16.2% |
| Q4 FY2024 | Dec 31, 2024 | $3.51M | +17.8% |
| Q3 FY2024 | Sep 30, 2024 | $2.86M | +2.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.83M | -33.0% |
| Q1 FY2024 | Mar 31, 2024 | $3.05M | -15.1% |
| Q4 FY2023 | Dec 31, 2023 | $2.98M | +6.6% |
| Q3 FY2023 | Sep 30, 2023 | $2.80M | +12.3% |
| Q2 FY2023 | Jun 30, 2023 | $4.21M | +37.1% |
| Q1 FY2023 | Mar 31, 2023 | $3.60M | +131.6% |
| Q4 FY2022 | Dec 31, 2022 | $2.80M | +57.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.49M | +103.4% |
| Q2 FY2022 | Jun 30, 2022 | $3.07M | +181.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.55M | -4.9% |
| Q4 FY2021 | Dec 31, 2021 | $1.78M | -21.7% |
| Q3 FY2021 | Sep 30, 2021 | $1.23M | +61.6% |
| Q2 FY2021 | Jun 30, 2021 | $1.09M | +54.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.63M | +219.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.28M | +189.1% |
| Q3 FY2020 | Sep 30, 2020 | $758.20K | +12.0% |
| Q2 FY2020 | Jun 30, 2020 | $706.17K | +64.9% |
| Q1 FY2020 | Mar 31, 2020 | $510.62K | +63.1% |
| Q4 FY2019 | Dec 31, 2019 | $787.83K | +168.7% |
| Q3 FY2019 | Sep 30, 2019 | $676.97K | +59.4% |
| Q2 FY2019 | Jun 30, 2019 | $428.31K | +52.7% |
| Q1 FY2019 | Mar 31, 2019 | $313.01K | +30.2% |
| Q4 FY2018 | Dec 31, 2018 | $293.24K | -16.0% |
| Q3 FY2018 | Sep 30, 2018 | $424.60K | +885.9% |
| Q2 FY2018 | Jun 30, 2018 | $280.42K | +51.6% |
| Q1 FY2018 | Mar 31, 2018 | $240.49K | – |
| Q4 FY2017 | Dec 31, 2017 | $349.09K | – |
| Q3 FY2017 | Sep 30, 2017 | $43.07K | – |
| Q2 FY2017 | Jun 30, 2017 | $184.92K | – |
See a number that looks wrong?